Loading Events

« All Events



With the rising costs of care due to aging population and elevated burden of chronic disease, there has been an increasing momentum for innovation in healthcare payment and delivery systems. Healthcare systems across the world have adopted Health Technology Assessments (“HTA”) to drive value-based care and developing real-world evidence for care innovation.

EuroCham with Deloitte as venue host held an industry information sharing seminar where Industry and Health Economics experts shared insights, best practices and organisational experiences from working with HTA systems in other jurisdictions. The seminar also included a panel discussion where industry experts discussed challenges and opportunities in developing HTA based submissions and the required organizational capabilities and competencies. 

Well-attended by pharmaceutical and medical technology industry professionals, the event ended on a high note with Robert Bowers from Singapore Association of Pharmaceutical Industries (SAPI), Anthony Morton-Small of Vista Health Pte Ltd, Alice Morgan of Deloitte Australia, Patrick Tung from AstraZeneca and Mohit Grover of Deloitte Singapore fielding numerous questions from the audience.





09:00 – 09:15 Registration and coffee/tea
09:15 – 09:30 Opening
09:30 – 10:00 Presentations by Deloitte and Vista Health
10:00 – 10:45 Panel Discussion
10:45 – 11:15 Questions & Answers
11:15 – 11:30 Networking

Meet the speakers


Patrick Tung
Head of Market Access Oncology

Patrick is the Head of Market Access Oncology for AstraZeneca International Region. He is responsible for the development and implementation of strategies to ensure patient access to AstraZeneca’s oncology medicines.

Patrick joins AZ from Merck, where he held the role of Head of Market Access and Pricing APAC since 2013. In this role, he established the Market Access and Pricing function in Japan, Korea, Taiwan, Indonesia, Vietnam, India and a sub-region, including Thailand, Philippines, Malaysia and Singapore. He has many years’ experience in the pharmaceutical industry, having held roles in Market Access, Business Development and Health Economics in other pharmaceutical organizations.

Alice Morgan
Director, Health Economics and Social Policy
Deloitte Access Economics, Australia

Alice is a Director in the Health Economics and Social Policy team of Deloitte Access Economics. She has over 10 years’ experience in the pharmaceutical sector in Australia and globally, including for government and industry.

Alice specialises in pharmaceuticals and health technology assessment and is experienced in pharmacoeconomics, health economics, literature review and quantitative analysis.


Robert Bowers
Singapore Association of Pharmaceutical Industries (SAPI)

Robert Bowers is the General Manager of GlaxoSmithKline (GSK) Singapore. Robert is also a member of the Singapore Association of Pharmaceutical Industries (SAPI) board, and is chair of the Market Access Committee.

Robert is responsible for GSK’s commercial operations in Singapore, driving business excellence for the pharmaceuticals and vaccines business presence here. Prior to that, Robert was the Global Commercial Lead for Cabotegravir at ViiV Healthcare based in the UK. He was responsible for leading the global commercial development of new long acting medicines for the treatment and prevention of HIV through PhIII development, to filing and launch. He also founded the HIVE, a digital innovation unit to focus on beyond the pill health solutions for people living with HIV.

Anthony Morton-Small
Managing Director
Vista Health

Anthony specializes in healthcare consulting in market access, growth strategy & portfolio management with 100+ client assignments covering Asia Pacific & Emerging Markets spanning 9 years in the region and is on the advisory board of MyDoc – Asia’s leading digital health player.

Previously, he was Senior Principal for IMS Consulting Group’s Asia Pacific Singapore office. He has led client engagements and thought leadership in emerging markets entry, operating plays and growth acceleration strategy as well as Government & Industry health policy Over 20 years of life science experience, at GSK & IMS Health advising multinational & local pharma, consumer health, med tech, providers, health ministries, NGOs & financial firms in Asia, EMEA & LatAm Has expert capabilities in: commercial excellence, commercial model innovation, launch, brand and franchise management, portfolio optimisation, emerging markets, growth strategies, market entry planning, pricing, market access, health policy, digital health and learning & development.


Mohit Grover
Executive Director
Life science & Healthcare Industry Leader, Risk Advisory, SEA
Deloitte Southeast Asia
Mohit is an Executive Director in Deloitte SEA and leads the Life Sciences and Healthcare industry. With 20 years of experience in Consulting and Life Sciences industries, he possesses in-depth expertise in enabling business growth strategies, strategic risk management and large scale transformations in Commercial, Finance and IT functions.

Prior to joining Deloitte Mohit held regional and global leadership positions in AstraZeneca, a global Pharmaceutical company. Mohit led initiatives across a range of strategic topics including innovation in commercial selling models, shared services and enterprise applications. His experience will prove invaluable in helping organizations tap into the market growth potential in South East Asia and address areas of building organization capabilities, market access, regulatory compliance and risks management.